HBB rs121908872: Understanding Beta-Zero Thalassemia Variants
The rs121908872 variant is a specific genetic change in the HBB gene that results in a premature stop signal during protein synthesis. This variant is associated with beta-zero thalassemia, a condition characterized by a significant reduction or total absence of adult hemoglobin beta-chain production.
What each genotype means
Typical hemoglobin production
This genotype represents the wild-type sequence for the HBB gene at this position. Individuals with this profile do not carry the specific nonsense variant associated with beta-zero thalassemia at this site.
This is the most common genotype in the general population, found in the vast majority of individuals across all ancestries.
Beta-thalassemia carrier status
This genotype indicates you are a carrier of the p.Gln39Ter nonsense variant, which leads to early translation termination of the beta-globin protein. Carriers are typically asymptomatic but may have mild hematological changes; you should discuss this result with a healthcare provider or genetic counselor to understand implications for family planning.
Carried by approximately 1 in 33 individuals (3%) in Southern European and Mediterranean cohorts, based on a reported allele frequency of 0.015.
Beta-zero thalassemia risk
This genotype indicates the presence of two copies of the nonsense variant, which prevents the production of functional beta-globin protein. This condition is associated with beta-zero thalassemia, a form of anemia that can range in severity from transfusion-dependent thalassemia major to thalassemia intermedia. Clinical management and diagnostic confirmation by a medical professional are essential.
This genotype is very rare, occurring at a frequency of approximately 0.000225 (or roughly 1 in 4,444) in populations where the allele frequency is 0.015.
What is rs121908872?
The rs121908872 variant is a single nucleotide polymorphism (SNP) located within the HBB gene on chromosome 11. Specifically, this variant is classified as a nonsense mutation, meaning it introduces a premature stop codon (p.Gln39Ter) in the genetic sequence. Instead of the cellular machinery reading the full instructions to build the beta-globin protein, the process terminates early. This truncated protein is typically unstable and rapidly degraded by the body, leading to a deficiency in functional beta-globin chains. Because this variant prevents the production of the protein entirely, it is categorized as a beta-zero thalassemia mutation. It sits in a critical region of the gene where even small changes can have profound effects on the stability and quantity of hemoglobin produced by red blood cells.
The Role of the HBB Gene
The HBB gene provides instructions for making a protein called beta-globin, which is a vital component of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen from the lungs to the rest of the body. In adults, normal hemoglobin (HbA) is composed of two alpha-globin chains and two beta-globin chains. When the HBB gene is mutated, the production of beta-globin can be reduced (beta-plus thalassemia) or completely absent (beta-zero thalassemia). This imbalance leads to an excess of alpha-globin chains, which can damage red blood cells and lead to anemia. The HBB gene is highly conserved, and its proper function is essential for maintaining healthy oxygen transport and preventing the complications associated with hemoglobinopathies.
Research and Clinical Evidence
Research into rs121908872 is primarily focused on its role as a pathogenic variant in the context of beta-thalassemia. Clinical databases and genetic studies classify this variant as a cause of beta-zero thalassemia when inherited in a biallelic pattern—meaning an individual inherits the variant from both parents or inherits it alongside another pathogenic HBB variant. The evidence for its pathogenicity is strong, as the nonsense mutation directly disrupts the translation of the beta-globin protein. While the clinical impact is well-documented in medical literature, the severity of the resulting phenotype can vary depending on the presence of other genetic modifiers or co-inherited variants. It is important to note that this information is for educational purposes and does not constitute a medical diagnosis or clinical advice.
Population Frequency
The rs121908872 variant is not evenly distributed across the globe. It is most frequently observed in Southern European and Mediterranean populations, where the carrier frequency is approximately 0.015. Because thalassemia variants often provided a survival advantage against malaria in historical contexts, they remain more common in regions where malaria was historically endemic. In other global populations, this specific variant is significantly rarer or absent. Understanding these frequency patterns is a key component of population genetics and helps researchers track the movement and history of specific genetic traits across different ancestral groups.
Managing Genetic Information
If you have received information about your carrier status for rs121908872, it is important to understand what this means in a broader context. Being a carrier typically means you have one copy of the variant and one normal copy of the HBB gene, which usually does not result in significant health issues. However, if you are planning a family, you may wish to discuss the implications of carrier status with a genetic counselor or your primary healthcare provider. They can provide context regarding the risks of passing the variant to offspring and explain the inheritance patterns of thalassemia. You cannot use this information to diagnose yourself or others; always consult with a qualified medical professional to interpret genetic test results in the context of your personal and family health history.
How common is this variant?
The rs121908872 variant has a reported frequency of approximately 0.015 in Southern European and Mediterranean cohorts.
Frequently asked questions
What is beta-zero thalassemia?
Beta-zero thalassemia is a blood disorder where the body produces little to no beta-globin, a necessary component of hemoglobin. This leads to a shortage of healthy red blood cells and can cause anemia.
Does having this variant mean I have a disease?
Not necessarily. If you have only one copy of the variant, you are likely a carrier and may not experience symptoms. If you have two copies, you may have a form of thalassemia, which requires evaluation by a medical professional.
How is this variant inherited?
This variant follows an autosomal recessive inheritance pattern. This means that a child must inherit a variant copy from both parents to be at risk for the clinical symptoms of the condition.
Should I be concerned about my carrier status?
Carrier status is generally asymptomatic, but it is relevant for family planning. You should discuss your results with a genetic counselor to understand the implications for your health and your family.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121908872?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in HBB
This variant is a pathogenic mutation in the HBB gene associated with beta-thalassemia.
This variant is a pathogenic mutation in the HBB gene associated with hemoglobinopathies such as sickle cell disease.
This variant (c.20A>T, p.Glu7Val) causes the substitution of valine for glutamic acid in the beta-globin chain, leading to sickle cell trait or disease depending on zygosity.
Pathogenic variant (p.Glu6Val, HbS-Antilles) in HBB associated with sickle cell disease-like pathology.
Pathogenic nonsense mutation (c.118C>T / p.Gln40Ter / codon 39 nonsense) causing beta-zero thalassemia and classic carrier status (beta-thalassemia minor).
This variant, known as Hb C-Harlem, involves a double mutation in the HBB gene that can lead to sickle-beta-thalassemia-like phenotypes.